医学分子生物学杂志2026，Vol.23Issue(2)：143-149,7.DOI:10.3870/j.issn.1672-8009.2026.02.005
芪红胶囊对冠状动脉微血管疾病小鼠血管内皮细胞氧化应激的影响
Effect of Qihong Capsules on Oxidative Stress in Vascular Endothelial Cells of Mice with Coronary Microvascular Disease
摘要
Abstract
Objective To investigate the effect of Qihong capsules on mitochondrial oxidative stress in mice with coronary microvascular disease(CMVD)via the TLR4/NF-κB/GPX4 path-way.Methods Twenty CMVD model mice were randomly assigned to 2 groups:model group and Qihong capsules treatment group[0.648 g/(kg·d),intragastric administration for 4 weeks],and additional 10 mice were served as the control group.Hematoxylin-eosin(HE)staining,oil red O staining,and immunohistochemistry were employed to assess coronary pathology and macrophage infiltration.Western blotting and enzyme-linked immunosorbent assay(ELISA)were utilized to de-tect the expression of relevant proteins and levels of reactive oxygen species(ROS).Results Com-pared with the control group,the model group exhibited severe coronary artery injury,elevated ex-pression of inflammatory cytokines(TNF-α,IL-1β,IL-6),enhanced activation of the TLR4/NF-κB pathway,downregulated expression of GPX4,Sirt1,and HO-1,and increased ROS levels(all P<0.001).Following intervention with Qihong capsules,the aforementioned pathological changes were significantly ameliorated,inflammation and oxidative stress were suppressed,and the expression of protective proteins was upregulated(all P<0.001).Conclusion Qihong capsules can alleviate oxidative stress by inhibiting the TLR4/NF-κB inflammatory pathway and upregulating the expression of GPX4/Sirt1/HO-1,thereby improving microvascular dysfunction in CMVD mice.Its mechanism may be associated with the inhibition of ferroptosis,reflecting its potential for multi-target intervention.关键词
冠状动脉微血管疾病/芪红胶囊/氧化应激/TLR4/NF-κB/GPX4通路/铁死亡Key words
coronary microvascular disease/Qihong capsule/oxidative stress/TLR4/NF-κB/GPX4 pathway/ferroptosis分类
医药卫生引用本文复制引用
高玉,王晓峰,姜海兵,吴竞辉,范辉..芪红胶囊对冠状动脉微血管疾病小鼠血管内皮细胞氧化应激的影响[J].医学分子生物学杂志,2026,23(2):143-149,7.基金项目
2023年度"天山英才"医药卫生人才培养计划项目(No.TSYC202301B053、No.TSYC202301B169) This work was supported by grants from the 2023"Tianshan Talent"Medical and Health Talent Training Program(No.TSYC202301B053,No.TSYC202301B169) （No.TSYC202301B053、No.TSYC202301B169）
